Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
Trial record 1 of 1 for:    NCT02558231
Previous Study | Return to List | Next Study

The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension (TRITON)

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2016 by Actelion
Information provided by (Responsible Party):
Actelion Identifier:
First received: September 22, 2015
Last updated: September 15, 2016
Last verified: September 2016
The objective of this clinical trial is to compare the efficacy and safety of an initial triple oral treatment regimen (macitentan, tadalafil, selexipag) versus an initial dual oral treatment regimen (macitentan, tadalafil, placebo) in newly diagnosed, treatment-naïve patients with pulmonary arterial hypertension.

Condition Intervention Phase
Pulmonary Arterial Hypertension
Drug: Macitentan
Drug: Tadalafil
Drug: Selexipag
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension: A Multi-center, Double-blind, Placebo-controlled, Phase 3b Study

Resource links provided by NLM:

Further study details as provided by Actelion:

Primary Outcome Measures:
  • Pulmonary vascular resistance [ Time Frame: Baseline to Week 26 ]
    As measured by right heart catheterization

Estimated Enrollment: 144
Study Start Date: May 2016
Estimated Study Completion Date: December 2018
Estimated Primary Completion Date: December 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Triple oral combination treatment
Macitentan, tadalafil, and selexipag
Drug: Macitentan
Used open-label in both arms, 10 mg tablet, 1 tablet u.i.d.
Drug: Tadalafil
Used open-label in both arms, 20 mg tablet, 1-2 tablets u.i.d.
Drug: Selexipag
Used double-blind in the triple oral treatment arm, 200 microgram tablet, 1-8 tablets b.i.d.
Placebo Comparator: Dual oral combination treatment
Macitentan, tadalafil, and placebo
Drug: Macitentan
Used open-label in both arms, 10 mg tablet, 1 tablet u.i.d.
Drug: Tadalafil
Used open-label in both arms, 20 mg tablet, 1-2 tablets u.i.d.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Signed informed consent prior to any study-mandated procedure.
  2. Male or female ≥ 18 and ≤ 75 years of age at screening.
  3. Initial PAH diagnosis < 6 months prior to enrollment.
  4. RHC performed between Day −28 and Day 1, meeting all the following criteria:

    • Mean pulmonary artery pressure (mPAP) ≥ 25 mmHg.
    • Pulmonary artery wedge pressure or left ventricular end-diastolic pressure ≤ 15 mmHg.
    • PVR ≥ 480 dyn•sec/cm5 (≥ 6 Wood Units).
    • Negative vasoreactivity test mandatory in idiopathic, heritable, and drug/toxin induced PAH (at this or a previous RHC).
  5. Symptomatic PAH belonging to one of the following subgroups:

    • Idiopathic.
    • Heritable.
    • Drug or toxin induced.
    • Associated with one of the following: connective tissue disease; HIV infection; congenital heart disease.
  6. 6-minute walk distance (6MWD) ≥ 50 m at screening.
  7. Women of childbearing potential must not be pregnant, must perform regular pregnancy tests, and use reliable contraception.

Exclusion Criteria:

  1. Any PAH-specific drug therapy at any time.
  2. Cardio pulmonary rehabilitation program based on exercise (planned, or started ≤ 12 weeks prior to Day 1).
  3. Body mass index (BMI) > 40 kg/m2 at screening.
  4. Presence of three or more of the following risk factors for heart failure with preserved ejection fraction at screening:

    • BMI > 30 kg/m2.
    • Diabetes mellitus of any type.
    • Essential hypertension.
    • Coronary artery disease, i.e., any of the following:

      • History of stable angina or
      • More than 50% stenosis in a coronary artery (by coronary angiography) or
      • History of myocardial infarction or
      • History of or planned coronary artery bypass grafting and/or coronary artery stenting.
  5. Acute myocardial infarction ≤ 12 weeks prior to screening.
  6. Stroke ≤ 12 weeks prior to screening.
  7. Known permanent atrial fibrillation.
  8. SBP < 90 mmHg at screening or Day 1.
  9. Ongoing or planned treatment with organic nitrates and/or doxazosin.
  10. Presence of one or more of the following signs of relevant lung disease at any time up to screening:

    • Diffusing capacity of the lung for carbon monoxide (DLCO) < 40% of predicted (eligible only if no or mild interstitial lung disease on computed tomography).
    • Forced vital capacity (FVC) < 60% of predicted.
    • Forced expiratory volume in one second (FEV1) < 60% of predicted.
  11. Known or suspected pulmonary veno-occlusive disease (PVOD).
  12. Documented severe hepatic impairment (with or without cirrhosis) according to National Cancer Institute organ dysfunction working group criteria, defined as total bilirubin > 3 × upper limit of the normal range (ULN) accompanied by aspartate aminotransferase (AST) > ULN (assessed by central laboratory at screening); and/or Child-Pugh Class C.
  13. Serum AST and/or alanine aminotransferase (ALT) > 3 × ULN (assessed by central laboratory at screening).
  14. Severe renal impairment (estimated creatinine clearance ≤ 30 mL/min/1.73 m2) assessed by central laboratory at screening.
  15. Ongoing or planned dialysis.
  16. Hemoglobin < 100 g/L assessed by central laboratory at screening.
  17. Known or suspected uncontrolled thyroid disease (hypo- or hyperthyroidism).
  18. Loss of vision in one or both eyes because of non-arteritic ischemic optic neuropathy (NAION).
  19. Treatment with strong inducers of cytochrome P450 3A4 (CYP3A4; e.g., carbamazepine, rifampin, rifampicin, rifabutin, rifapentin, phenobarbital, phenytoin, and St. John's wort) ≤ 28 days prior to Day 1.
  20. Treatment with strong inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, nefazodone, ritonavir, and saquinavir) ≤ 28 days prior to Day 1.
  21. Treatment with another investigational drug (planned, or taken ≤ 12 weeks prior to Day 1).
  22. Hypersensitivity to any of the 3 study treatments or any excipient of their formulations.
  23. Pregnancy, breastfeeding, or intention to become pregnant during the study.
  24. Concomitant life-threatening disease with a life expectancy < 12 months.
  25. Alcohol abuse.
  26. Any factor or condition likely to affect protocol compliance of the subject, as judged by the investigator.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02558231

Contact: Loic Perchenet

  Show 37 Study Locations
Sponsors and Collaborators
  More Information

Responsible Party: Actelion Identifier: NCT02558231     History of Changes
Other Study ID Numbers: AC-065A308
Study First Received: September 22, 2015
Last Updated: September 15, 2016

Additional relevant MeSH terms:
Familial Primary Pulmonary Hypertension
Vascular Diseases
Cardiovascular Diseases
Hypertension, Pulmonary
Lung Diseases
Respiratory Tract Diseases
Antihypertensive Agents
Endothelin A Receptor Antagonists
Endothelin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action
Endothelin B Receptor Antagonists
Vasodilator Agents
Phosphodiesterase 5 Inhibitors
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Urological Agents processed this record on May 25, 2017